[Skip to content]

Royal Brompton & Harefield NHS Foundation Trust
Our research
Search our Site

Trust research on show at world’s largest cardiology congress

Tina Khan European Society of Cardiology Congress 2016 Rome
Dr Tina Khan presenting her research at the European Society of Cardiology Congress in Rome

Cardiovascular clinical research from Royal Brompton & Harefield NHS Foundation Trust was well represented at the European Society of Cardiology (ESC) Congress, held this year in Rome from 27 to 31 August. Trust researchers took part in a number of research presentations and training sessions throughout the congress.

This event is recognised as the world’s largest and most influential congress for cardiovascular professionals. Specialists from across the globe attended to discuss cutting edge science and innovations, network and learn as part of the fight against cardiovascular disease.


Dr Tina Khan, clinical research fellow from the NIHR Royal Brompton Cardiovascular Biomedical Research Unit presented her research investigating the role lipoprotein apheresis in treating patients with refractory angina and raised lipoprotein(a) in the 'late breaking science: prevention and lipids hot line' session. 

This prestigious session provided Dr Khan with the opportunity for her research to be presented, reviewed and discussed with the help of an expert panel, on its relevance in future research and patient care. 

Dr Khan explains: "For patients suffering with refractory angina, treatment options can be limited. Our trial provides the first evidence that lipoprotein apheresis leads to an improvement in myocardial blood flow and a reduction in symptoms for these patients, leading to an improvement in their quality of life. The results suggest that this could represent a much-needed new treatment option for patients with this challenging condition.


"Presentation of this clinical trial to a wide audience at this international forum has thrown a spotlight on Lipoprotein(a) as an important and underappreciated causal risk factor for cardiovascular disease; and will guide further research into the role of lowering lipoprotein(a) to reduce the burden of heart disease."

September 2016 


Back to BRU news